Skip to main content

Table 2 Baseline comorbidities of the patients

From: Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

 

Total

Non-squamous

Squamous

p-value

Comorbidities

   

< 0,001

None

1.530 (17,4%)

1.334 (18,7%)

196 (11,7%)

 

At least one

7.266 (82,6%)

5.785 (81,3%)

1.481 (88,3%)

 

Hypertension (HT)

3.704 (42,1%)

2.904 (40,8%)

800 (47,7%)

< 0,001

Dyslipidemia

2.499 (28,4%)

1.992 (28,0%)

507 (30,2%)

0,066

Diabetes Mellitus (DM)

1.652 (18,8%)

1.242 (17,4%)

410 (24,4%)

< 0,001

Chronic Obstructive Pulmonary Disease (COPD)

1.588 (18,1%)

1.092 (15,3%)

496 (29,6%)

< 0,001

Cardiomyopathy

1.293 (14,7%)

960 (13,5%)

333 (19,9%)

< 0,001

Depression/Anxiety

642 (7,3%)

543 (7,6%)

99 (5,9%)

0,014

Former Alcoholism

635 (7,2%)

493 (6,9%)

142 (8,5%)

0,031

Hypercholesterolemia

619 (7,0%)

498 (7,0%)

121 (7,2%)

0,750

Vasculopathy

481 (5,5%)

366 (5,1%)

115 (6,9%)

0,007

Obesity

333 (3,8%)

259 (3,6%)

74 (4,4%)

0,136

Nephropathy

236 (2,7%)

179 (2,5%)

57 (3,4%)

0,053

Hepatitis

177 (2,0%)

140 (2,0%)

37 (2,2%)

0,500

Asthma

171 (1,9%)

145 (2,0%)

26 (1,6%)

0,237

Tuberculosis

137 (1,6%)

110 (1,5%)

27 (1,6%)

0,827

Other

3.881 (44,1%)

3065 (43,1%)

816 (48,7%)

< 0,001